MyVisionTest News Archive

Displaying news items tagged with CATT (More tags »)
SELECT PAGE
First <<  1 2   >> Last

Eylea
Jan 16, 2012
Genentech and Regeneron Pharmaceuticals have agreed to a partial settlement with regard to ophthalmic sales of aflibercept injections in the United States, according to a press release. Under the plan, Regeneron will receive a non-exclusive license to certain patents for VEGF receptor proteins as well as to other technology patents, the release...

Full Article


CATT trial logo
Jan 15, 2012
The long-awaited primary outcome of the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) study was that patients receiving either monthly Avastin (bevacizumab) or monthly Lucentis (ranibizumab) had equivalent visual acuity at 1 year. For the majority of clinicians who already preferentially used Avastin for age-related...

Full Article


CATT trial logo
Jan 15, 2012
The much anticipated CATT study has now been published. The National Eye Institute is to be applauded for having sponsored this landmark trial and for setting a new standard of transparency by submitting most of the raw data on the Internet. Millions of people who cannot afford Lucentis (ranibizumab) now have the benefit of a high level of...

Full Article


CATT trial logo
Jan 14, 2012
For 5 years, patients and clinicians have wrestled with the choice between two drugs for the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF), the cytokine primarily responsible for blood-vessel growth, is inhibited when anti-VEGF drugs are injected repeatedly into the eye, and blindness is...

Full Article


Avastin
Jan 14, 2012
Intraocular injections of anti–vascular endothelial growth factor (VEGF) agents have yielded dramatic improvements in the management of a wide variety of neovascular ocular diseases including age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion, and retinopathy of prematurity. These agents have thus become...

Full Article


CATT trial logo
Jan 8, 2012
Avastin and Lucentis had equivalent effects on visual acuity at 1 year, accirding to the much anticipated Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) research group. Clinical trials have established the efficacy of Lucentis (ranibizumab) for the treatment of neovascular age-related macular degeneration (AMD). In...

Full Article


Intravitreal injection
Jan 20, 2011
Ocular anti-VEGF therapy has presented a major breakthrough in the care of patients with exudative AMD, giving rise to a wide array of therapeutic strategies among ophthalmologists, with no consensus on optimal practices. As an alternative to the strict regimen of monthly intravitreal injection used in the protocols of the pivotal ranibizumab...

Full Article


Age-related macular degeneration
Feb 24, 2010
There is no difference in the visual acuity (VA) outcomes after Avastin (bevacizumab) or Lucentis (ranibizumab) treatment for AMD, according to a new study. In 2006, the United States Food and Drug Administration approved the use of Lucentis (ranibizumab) for the treatment of exudative AMD. Before its approval, many ophthalmologists already...

Full Article


CATT trial logo
Jan 26, 2010
The first major clinical trial to compare bevacizumab and ranibizumab in a head-to-head fashion has completed enrollment, and the first data analysis is expected in about 1 year. Although the head-to-head comparison of Avastin (bevacizumab, Genentech) and Lucentis (ranibizumab, Genentech) in CATT (Comparisons of age-related macular degeneration...

Full Article


Macular degeneration
Oct 26, 2009
Investigators have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Avastin (bevacizumab) and Lucentis (ranibizumab) for the treatment of age-related macular degeneration (AMD). The study is the first to report early outcomes of a prospective, double-masked, randomized, controlled trial comparing...

Full Article


SELECT PAGE
First <<  1 2   >> Last
Most Popular
Less - past - More